CLDN18 and neoplasm: This phase III trial randomised 575 patients to either zolbetuximab or placebo using mFOLFOX6 (5-FU, leucovorin and oxaliplatin combination chemotherapy) as the chemotherapy backbone and included patients with moderate-to-strong CLDN18 staining in ≥75% of tumour cells on IHC.